<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850317</url>
  </required_header>
  <id_info>
    <org_study_id>08-377</org_study_id>
    <nct_id>NCT00850317</nct_id>
  </id_info>
  <brief_title>Fanconi Anemia Transplant Lacking Genotypically Identical Donor</brief_title>
  <official_title>Multicenter Phase II Trial-Hematopoietic Stem Cell Transplantation for Treatment of Patients With FA Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study for patients with Fanconi Anemia whose bone marrow has changed and now
      failed, giving rise to a pre-leukemia or leukemia. This study is a Phase II clinical trial
      in which patients will undergo allogenic transplant of stem cells, meaning they will receive
      bone marrow cells from a healthy donor. The purpose of this study is to see if transplant
      course of treatment will lower the risk of graft vs. host disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence and quality of engraftment and hematopoietic reconstitution, the incidence of early transplant related mortality, the incidence and severity of acute GvHD and chronic GVHD.</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of severe post transplant regimen-related severe morbidity (grade III/IV toxicity) and/or mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced-intensity transplant with non-TBI containing regimen for Fanconi ANemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Miltenyi CliniMACs device</intervention_name>
    <description>CD34 selection</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis: Patients must have a diagnosis of Fanconi anemia (confirmed by mitomycin C
             or diepoxybutane [DEB] chromosomal breakage testing at an approved laboratory)

          -  Hematologic Diagnosis and Status: Patients must have one of the following hematologic
             diagnoses:

               1. Severe Aplastic Anemia (SAA), or Severe Isolated Single lineage

                  Cytopenia with bone marrow cellularity of &lt; 25% AND at least one of the
                  following features:

                    -  Platelet count &lt; 20 x 109/L or platelet transfusion dependence

                    -  ANC &lt; 1000 x 109/L

                    -  Hgb &lt; 8 gm/dl or red cell transfusion dependence

               2. Myelodysplatic Syndrome (MDS) (Appendix 1: MDS Classification). MDS at any
                  stage, based on either one of the following classifications:

                    -  WHO Classification

                    -  Refractory anemia and transfusion dependence

                    -  Any of other stages

                    -  IPSS Classification

                    -  Low risk (score 0) and transfusion dependence

                    -  Any other risk groups Score &gt; 0.5

               3. Acute Myelogenous Leukemia: Patients with acute leukemia are included in this
                  trial in remission, refractory or relapsed disease

        Exclusion Criteria:

          -  Active CNS leukemic involvement

          -  Female patients who are pregnant or breast-feeding

          -  Active uncontrolled viral, bacterial or fungal infection

          -  Patient seropositive for HIV-I/II; HTLV -I/II
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amber Smith</last_name>
      <phone>617-355-3748</phone>
      <email>amber.smith@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Chirnomas, M.D.</last_name>
      <phone>617-632-6798</phone>
      <email>deborah_chirnomas@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David A Williams, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Chirnomas, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <lastchanged_date>February 24, 2009</lastchanged_date>
  <firstreceived_date>February 24, 2009</firstreceived_date>
  <responsible_party>
    <name_title>David A. Williams, MD</name_title>
    <organization>Children's Hospital Boston and Dana Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>Fanconi Anemia</keyword>
  <keyword>FA</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>T-Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
